Eleusis SPAC

Rapid, Robust, and Durable Antidepressant Effects of Psychedelics Academic Preclinical and Clinical Study Observations Serotonergic psychedelics eleusis 5-HT 2A receptor huw 5-HT 1A receptor (+) Downstream GPCR pathways [Ca²+] depolarization Glutamate release AMPA receptor vini -0000-00- AMPAR GluA1 Tthroughput TPSD95 BDNF release mTORC1 Induction of neuroplasticity eEF2 BDNF OtrkB Increase. plasticity tion Modulated pathways associated with synaptic growth in preclinical studies ¹ Rapid, robust, and durable antidepressant effects observed in third party clinical trials² Potential to open a "critical window" for adaptation and behavior change³ Source: 1) Kadriu et al., Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants, Int J Neurops, 1(24), 2020 2) Carhart-Harris, R.L,et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402-1411; Compass Pathways Press Release, 11/9/2021; https://compasspathways.com/positive-topline-results/); Davis, A. K., et al. (2020). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry. 3) Publication in draft; partial results published in Nardou R et al (2019) Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature. 2019 May;569(7754):116-120. 10

View entire presentation